Background and study aim: Primary Ovarian insufficiency, which is described by significantly reduced ovarian reserve, menstrual irregularity, or amenorrhea earlier than 40 years of age, affects 1% of women at reproductive age. Recently, platelet-rich plasma (PRP) has been widely used in regenerative treatment in different fields, as it is rich with cytokines and growth factors. Accumulation of platelet in a tissue stimulates cell proliferation and tissue regeneration through protein secretion in response to cytokines, and growth factors. Recently, it has been investigated in the cases of ovarian insufficiency. This study aimed to evaluate whether the intra-ovarian injection of autologous PRP would improve ovarian reserve through ovarian rejuvenation thus causing spontaneous pregnancy or menstrual recovery in women with primary ovarian insufficiency.
Patients and Methods: This Quazi-Expermental study was conducted in the department of Obstetrics & Gynecology, Suez Canal University hospital. It was conducted on 38 Women of childbearing period presenting at the outpatient clinic of the Department of Obstetrics and Gynecology complaining of Primary ovarian insufficiency diagnosed according to ESHRE guideline. 
Results: Our study showed that FSH levels rose considerably, indicating a reduction in ovarian reserve. Although AMH levels remained relatively stable, there was a slight decrease in the median value, which could suggest a potential trend towards diminished reserve. AFC demonstrated a statistically significant decrease, with an increasing number of patients exhibiting 0 or 1 follicle after a two-month period.These results indicate a significant deterioration in ovarian reserve markers over 2 months, especially reflected by a rise in FSH and a drop in AFC.
Conclusion: In contrast to previous reports demonstrating improved ovarian reserve markers following PRP treatment, this study did not observe a favorable change in ovarian reserve two months post-intraovarian PRP in women with established POI. The findings underscore the need for longer follow-up, larger sample sizes, and standardization of PRP protocols. Future research should focus on identifying patient subgroups most likely to benefit from PRP and establishing biological markers predictive of response.